ClinicalTrials.gg
RecruitingNCT04643002Updated Oct 13, 2026

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

A Phase 1/2 interventional study of Isatuximab and Dexamethasone in Plasma Cell Myeloma Refractory, sponsored by Sanofi. Recruiting at 25 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 9 months later.
Updated Oct 13, 2026No longer in Puerto Rico1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Planned enrollment
35th of 373
258 · median 45
Started
2021
with 25 others
Phase 1/2
52 of 381
11 open now
Primary completion
2027-09
later than 66 of 103 live
Registered
295th of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 35th largest by planned enrollment of the 373 interventional ones that give a count, is one of 26 that started in 2021, is one of 52 in phase 1/2, reaches primary completion later than 66 of the 103 other live ones, and was the 295th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

Read the detailed description

Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.

03

Conditions studied

  • Plasma Cell Myeloma Refractory

Browse trials for

Keywords

  • anti-CD38 monoclonal antibody
  • master protocol
  • combination therapy
  • CD38 resistance
  • interleukin 2
  • ROCK2 inhibitor
  • anti-CD47 agent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years of age inclusive or older.
  • (ECOG) performance status 0-1.
  • Participants with MM who have received at least 2 for MM, including PIs and IMiDs (eg, Induction regimen with stem cell transplant followed by maintenance is considered one line).
  • RRMM with :

    • Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
    • Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
    • Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio \<0.26 or >1.65).
  • Men or woman or should agree to use .
  • Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.
  • Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.
  • Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.
  • Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.

Exclusion criteria

Exclusion Criteria:

  • Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
  • Uncontrolled infection within 14 days prior to first study intervention administration.
  • cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, \<40%, heart failure Classes III and IV, stroke, , pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by Version 5.0).
  • Known acquired immunodeficiency syndrome-related illness or known (HIV) disease requiring antiviral treatment or active hepatitis A.
  • Uncontrolled or active virus (HBV) infection.
  • Active virus (HCV) infection.
  • Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
  • Second other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
  • Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
  • Participants with a to treatment.
  • Vaccination with a 4 weeks before the start of the study.
  • Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
  • \<8 g/dL.
  • \<50 × 10\^9/L.
  • \<1.0 × 10\^9/L.
  • \<30 mL/min/1.73m2.
  • Total >1.5 × , except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
  • and/or alanine aminotransferase >3 × ULN.
  • Patients with grade 3 or 4 hypercalcemia.

Substudy 01:

-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.

Substudy 02:

  • History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
  • Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
  • or INR >1.5 × upper limit of normal (ULN).

Substudy 03:

  • Current corneal epithelial disease except mild punctate keratopathy.
  • Patients who have received prior therapy with belantamab mafodotin.

Substudy 04:

  • Central nervous system or .
  • Medical history of seizure.
  • Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
  • Active, known, or suspected disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, or drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
  • Prior hematopoietic stem cell transplant (allo-HSCT).

Substudy 05:

- Participant unable to swallow tablets.

Substudy 06:

  • History of active autoimmune disorders.
  • History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
  • Active (GVHD) or ongoing immunosuppression for GVHD.
  • Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
  • Patient with chronic active EBV infection.
  • Patients with known history of HLH.
  • Hemoglobin \< 9 g/dL.
  • Prior therapy with any anti-7 or anti signal regulatory protein alpha agent.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
258 participants (estimated)

Study arms

  • Active comparator
    Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)

    * Isatuximab, intravenous (IV) doseweekly (QW) × 4 weeks (Cycle 1), followed by every two weeks (Q2W) (subsequent cycles). * Pomalidomide dose by mouth daily Day 1 to Day 21. * Dexamethasone dose by mouth QW.

    Drug: Isatuximab · Drug: Dexamethasone · Drug: Pomalidomide

  • Experimental
    isatuximab + SAR439459 + dexamethasone (Substudy 02)

    SAR439459 in combination with isatuximab and dexamethasone Part 1: 2 dose levels (DLs) of IV SAR439459: * DL1 SAR439459 dose Q2W. * DL2 SAR439459 dose Q2W. * Isatuximab dose IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles). * Dexamethasone fixed dose and schedule: QW by mouth In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8). Part 2: * SAR439459 IV dose Q2W. * Isatuximab IV dose QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles). * Dexamethasone fixed dose and schedule: QW by mouth. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).

    Drug: Isatuximab · Drug: Dexamethasone · Drug: SAR439459

  • Experimental
    isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)

    Belantamab mafodotin in combination with isatuximab and dexamethasone Part 1: 1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1: * DL1 belantamab mafodotin IV dose QW4 or de-escalation dose DL-1 QW8 * Isatuximab dose, IV QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles). * Dexamethasone fixed dose and schedule: QW by mouth. Part 2: * Isatuximab IV dose QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles). * Belantamab mafodotin IV dose Q4W or Q8W * Dexamethasone fixed dose and schedule: QW by mouth.

    Drug: Isatuximab · Drug: Dexamethasone · Drug: Belantamab mafodotin

  • Experimental
    Isatuximab + pegenzileukin (Substudy 04)

    Pegenzileukin in combination with isatuximab Part 1- dose escalation: * Up to 3 DLs of IV pegenzileukin are planned to be evaluated: * DL1 will explore pegenzileukin at Q2W. * DL2 will explore pegenzileukin at Q2W. * DL3 will explore pegenzileukin at Q2W. * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles). Part 1 - dose optimization: * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles). * Pegenzileukin at potential doses (DL A and DL B) Q2W. Part 2 (dose expansion): * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles). * Pegenzileukin IV dose Q2W.

    Drug: Isatuximab · Drug: Pegenzileukin

  • Experimental
    Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)

    Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles. * Belumosudil by mouth at Dose Level (DL) 1, DL2, DL3, and DL4 * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles) * Dexamethasone fixed dose and schedule: QW by mouth Part 1- dose optimization: * Belumosudil at potential doses (DL A and DL B), daily by mouth * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles) * Dexamethasone fixed dose and schedule: QW by mouth Part 2- dose expansion: * Belumosudil dose daily, by mouth * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles) * Dexamethasone fixed dose and schedule: QW by mouth

    Drug: Isatuximab · Drug: Dexamethasone · Drug: Belumosudil

  • Experimental
    Isatuximab + evorpacept + dexamethasone (Substudy 06)

    Isatuximab in combination with evorpacept and dexamethasone Part 1- dose escalation: * Evorpacept IV dose Q2W * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles) * Dexamethasone fixed dose and schedule: QW by mouth Part 1- dose optimization * Evorpacept IV at potential doses (DL A and DL B), Q2W * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles) * Dexamethasone fixed dose and schedule: QW by mouth Part 2- dose expansion: * Evorpacept IV dose Q2W * Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles) * Dexamethasone fixed dose and schedule: QW by mouth

    Drug: Isatuximab · Drug: Dexamethasone · Drug: Evorpacept

Interventions

  • Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

    Also known as: SAR650984, Sarclisa®

  • Pharmaceutical form: Tablet; Route of administration: Oral

  • Pharmaceutical form: Capsule; Route of administration: Oral

    Also known as: Pomalyst®

  • Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

    Also known as: BLENREP®

  • Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

    Also known as: SAR444245

  • Pharmaceutical form: Solution for injection; Route of administration: Intravenous

  • Pharmaceutical form: tablet; route of administration: oral

    Also known as: SAR445761,, Rezurock

  • Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

    Also known as: ALX148

06

What researchers measure

Primary outcomes

  1. Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab

    Determination or confirmation of the dose will be based on: safety and tolerability in terms of TEAEs/SAEs, dose-limiting toxicity occurrence, and laboratory parameters available information on PK (if appropriate) and biomarkers.

    Time frame: Through the end of cycle 1 (approximately 6 weeks)

  2. Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)

    VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  3. Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies

    ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

Secondary outcomes

  1. Part 1 (dose finding, experimental substudies): ORR

    ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  2. Part 2 (expansion, controlled experimental substudies): ORR

    ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  3. Part 1 (dose finding, experimental substudies): VGPR or better

    VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  4. Part 2 (expansion, independent experimental substudies): VGPR or better

    VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  5. Clinical benefit rate (CBR) in each treatment arm

    CBR, defined as the proportion of participants with sCR, CR, VGPR, PR, or minimal response, according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  6. Duration of Response (DOR) in each treatment arm

    DOR, defined as the time from the date of the first response that is subsequently confirmed for patients achieving PR or better to the date of first documented PD or death, whichever happens first.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  7. Time to First Response (TT1R) in each treatment arm

    TT1R, defined as the time from the date of first treatment to the date of first response (PR or better) that is subsequently confirmed.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  8. Time to Best Response (TTBR) in each treatment arm

    TTBR, defined as the time from the date of first treatment to the date of first occurrence of best overall response (PR or better) that is subsequently confirmed.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  9. Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm

    Safety and tolerability assessed in terms of adverse events/SAEs, including second primary malignancies, laboratory parameters, vital signs, and findings from physical examination.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  10. Progression-free survival (PFS) in each treatment arm

    PFS is defined as the time from the date of first treatment to disease progression based on the Investigator assessment according to 2016 IMWG criteria or death from any cause, whichever happens first.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  11. Overall Survival (OS) in each treatment arm

    OS is defined as the time from the date of first treatment to death from any cause.

    Time frame: Up to approximately 28 months after the First patient in or scheduled assessment

  12. Immunogenicity of isatuximab and novel agents

    Incidence of anti-drug antibodies (ADAs) for novel agents (experimental arms) and isatuximab.

    Time frame: Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment

  13. Concentration of novel agents (experimental arms) and isatuximab (Ctrough)

    Time frame: Multiple timepoints during Cycle 1. The cycle is 28 days.

  14. Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)

    The EORTC QLQ-C30 will be used to assess cancer-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

    Time frame: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

  15. Disease- and treatment-related quality of life will be assessed using the EORTC multiple myeloma module (QLQ-MY20) questionnaire

    The EORTC QLQ-MY20 will be used to measure myeloma-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

    Time frame: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

  16. Global impact of side effects will be assessed using the Functional Assessment of Cancer Therapy (FACT-G) (GP5)

    A single item from the FACT-G GP5 will be used to assess the global impact of side effects. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

    Time frame: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

  17. Estimate/Confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores using the Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales

    Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales will be utilized as anchors to estimate/confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

    Time frame: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

  18. The intensity of skeletal-related events (SRE)- related bone pain will be assessed using the skeletal-related bone pain numeric rating scale (SRE-BP-NRS) for control and experimental arms -Substudy 02

    The SRE-BP-NRS) will be used to assess the intensity of SRE-related bone pain (on average and at its worst) for control arm only

    Time frame: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

  19. SRE Incidence for control and experimental arms- Substudy 02

    SRE incidence, defined as the proportion of participants who experienced pathological fracture, radiation to bone, spinal cord compression, or surgery to bone as a first bone event.

    Time frame: Continuous throughout study assessment (up to approximately 28 months)

  20. Time to First Occurrence of SRE Assessment for control and experimental arms (Substudy 02)

    Time to first occurrence of SRE is defined as time from the date of randomization to the occurrence of first SRE.

    Time frame: Continuous throughout study assessment (up to approximately 28 months)

  21. Assessment of Health care resource utilization related with SREs for control and experimental arms -Substudy 02

    The Health Care Resource Use-SREs questionnaire (HCRU-SREs) will be used to assess the use of health care resources associated with these events.

    Time frame: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.

  22. To assess patient-reported visual functioning for experimental arm only -Substudy 03

    An NEI VFQ-25 will be used to assess patient-reported visual functioning.

    Time frame: On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.

  23. Maximum concentration observed after the first infusion (Cmax) for Belumosudil - Substudy 05

    Time frame: Multiple timepoints during Cycle 1. The cycle is 28 days.

  24. Time to reach Cmax (tmax) for Belumosudil - Substudy 05

    Time frame: Multiple timepoints during Cycle 1. The cycle is 28 days.

  25. Area under the concentration versus time curve calculated using the trapezoidal method from 0 to 8h (AUC0-8h) for Belumosudil - Substudy 05

    Time frame: Multiple timepoints during Cycle 1. The cycle is 28 days.

  26. Maximum concentration observed after the first infusion (Cmax) for Evorpacept - Substudy 06

    Time frame: Multiple timepoints during Cycle 1. The cycle is 28 days.

  27. Time to reach Cmax (tmax) for Evorpacept - Substudy 06

    Time frame: Multiple timepoints during Cycle 1. The cycle is 28 days.

  28. Area under the concentration versus time curve calculated using the trapezoidal method over the dosing interval for evorpacept (AUC0-t)- Substudy 06

    Time frame: Multiple timepoints during Cycle 1. The cycle is 28 days.

07

Study locations

24 of 25 sites recruiting
  • Winship Cancer Institute of Emory University- Site Number : 8400010
    Atlanta, Georgia 30322, United States
    Recruiting
  • University of Illinois-Chicago - College of Medicine- Site Number : 8400007
    Chicago, Illinois 60612, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Roswell Park Cancer Institute- Site Number : 8400008
    Buffalo, New York 14263, United States
    Recruiting
  • The Ohio State University- Site Number : 8400012
    Columbus, Ohio 43210, United States
    Recruiting
  • Investigational Site Number : 0360006
    Wollongong, New South Wales 2500, Australia
    Recruiting
  • Investigational Site Number : 0360002
    Melbourne, Victoria 3065, Australia
    Recruiting
  • Investigational Site Number : 0360001
    Richmond, Victoria 3121, Australia
    Recruiting
  • Investigational Site Number : 2500002
    Lille, 59037, France
    Recruiting
  • Investigational Site Number : 2500001
    Nantes, 44093, France
    Recruiting
  • Investigational Site Number : 2500003
    Paris, 75013, France
    Recruiting
  • Investigational Site Number : 2500004
    Paris, 75015, France
    Recruiting
  • Investigational Site Number : 2760006
    Frankfurt, 60590, Germany
    Recruiting
  • Investigational Site Number : 2760008
    Lübeck, 23562, Germany
    Recruiting
  • Investigational Site Number : 3000002
    Athens, 106 76, Greece
    Recruiting
  • Investigational Site Number : 3000001
    Athens, 115 28, Greece
    Recruiting
  • Investigational Site Number : 3760002
    Jerusalem, 9112001, Israel
    Recruiting
  • Investigational Site Number : 3760003
    Ramat Gan, 5262100, Israel
    Recruiting
  • Investigational Site Number : 3760001
    Tel Aviv, 6423906, Israel
    Recruiting
  • Investigational Site Number : 3800001
    Meldola, Reggio Emilia 47014, Italy
    Recruiting
  • Investigational Site Number : 5780001
    Oslo, 0450, Norway
    Recruiting
  • Investigational Site Number : 4100001
    Seoul, Seoul-teukbyeolsi 03080, South Korea
    Recruiting
  • Investigational Site Number : 4100004
    Seoul, Seoul-teukbyeolsi 03722, South Korea
    Recruiting
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 06351, South Korea
    Recruiting
  • Investigational Site Number : 4100003
    Seoul, Seoul-teukbyeolsi 06591, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Sep 2027, 79 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 79 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2020
First posted
Nov 24, 2020
StartActual
Jan 25, 2021
Primary completionEst.
Sep 13, 2027
CompletionEst.
Apr 20, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 2 sites removed; no longer in Puerto Rico
Show site
  • Investigational Site Number : 2500003 · Paris, France
Show 2 removed
  • Investigational Site Number : 2500003 · Paris, France
  • Puerto Rico Medical Research Center- Site Number : 8400005 · Hato Rey, Puerto Rico
Oct 13, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Investigational Site Number : 2500002 · Lille, FranceContact removed A•••@chu-lille.fr · •••5713Contact removed (no phone or email listed)
  • Investigational Site Number : 2500001 · Nantes, FranceContact removed d•••@chu-nantes.fr · •••2477Contact removed (no phone or email listed)
  • Investigational Site Number : 2500004 · Paris, FranceContact removed r•••@aphp.fr · •••5663Contact removed (no phone or email listed)
  • Investigational Site Number : 3800001 · Meldola, ItalyContact removed f•••@irst.emr.it · •••9442Contact removed (no phone or email listed)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added, 2 sites removed; no longer in Puerto Rico
    Show site
    • Investigational Site Number : 2500003 · Paris, France
    Show 2 removed
    • Investigational Site Number : 2500003 · Paris, France
    • Puerto Rico Medical Research Center- Site Number : 8400005 · Hato Rey, Puerto Rico
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Investigational Site Number : 2500002 · Lille, FranceContact removed A•••@chu-lille.fr · •••5713Contact removed (no phone or email listed)
    • Investigational Site Number : 2500001 · Nantes, FranceContact removed d•••@chu-nantes.fr · •••2477Contact removed (no phone or email listed)
    • Investigational Site Number : 2500004 · Paris, FranceContact removed r•••@aphp.fr · •••5663Contact removed (no phone or email listed)
    • Investigational Site Number : 3800001 · Meldola, ItalyContact removed f•••@irst.emr.it · •••9442Contact removed (no phone or email listed)
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04643002
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 24, 2020
Start date
Jan 25, 2021
Primary completion
Sep 13, 2027 (estimated)
Completion
Apr 20, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Trial Transparency email recommended (Toll free number for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6
Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion